Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab by Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin, Diana Muñoz Sandoval, Catherine J. Reynolds, Rocio Castro Seoane, Sherine H. Kottoor, Franziska P. Pieper, Kai-Min Lin, David K. Butler, Neil Chanchlani, Rachel Nice, Desmond Chee, Claire Bewshea, Malik Janjua, Timothy J. McDonald, Shaji Sebastian, James L. Alexander, Laura Constable, James C. Lee, Charles D. Murray, Ailsa L. Hart, Peter M. Irving, Gareth-Rhys Jones, Klaartje B. Kok, Christopher A. Lamb, Charlie W. Lees, Daniel M. Altmann, Rosemary J. Boyton, James R. Goodhand, Nick Powell, Tariq Ahmad, CLARITY IBD study

Get full text